Cargando…

Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

OBJECTIVE: We aimed to examine the association between bone morphogenetic protein-9 (BMP-9) and type 2 diabetes mellitus (T2DM) in conjunction with non-alcoholic fatty liver disease (NAFLD) and insulin resistance (IR) and to identify evidence supporting the potential role of BMP-9 in the clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Jianan, Wang, Yichao, Huo, Lijing, Sun, Tiantian, Zhen, Yunfeng, Gao, Zhe, Chen, Shuchun, Ren, Luping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741848/
https://www.ncbi.nlm.nih.gov/pubmed/36514745
http://dx.doi.org/10.2147/IJGM.S385513
_version_ 1784848403619905536
author Hao, Jianan
Wang, Yichao
Huo, Lijing
Sun, Tiantian
Zhen, Yunfeng
Gao, Zhe
Chen, Shuchun
Ren, Luping
author_facet Hao, Jianan
Wang, Yichao
Huo, Lijing
Sun, Tiantian
Zhen, Yunfeng
Gao, Zhe
Chen, Shuchun
Ren, Luping
author_sort Hao, Jianan
collection PubMed
description OBJECTIVE: We aimed to examine the association between bone morphogenetic protein-9 (BMP-9) and type 2 diabetes mellitus (T2DM) in conjunction with non-alcoholic fatty liver disease (NAFLD) and insulin resistance (IR) and to identify evidence supporting the potential role of BMP-9 in the clinical prevention and treatment of T2DM in conjunction with NAFLD. METHODS: One hundred and twenty subjects were included in this study. We sorted all of the subjects into four groups of equal size (n=30 each). A trained expert assessed the height, weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP) of the subjects and computed the body mass index (BMI). All subjects had their fasting blood glucose (FBG), fasting insulin (FINS), serum BMP-9, and biochemical indices assessed. RESULTS: Significant variations were observed in BMI, SBP, DBP, ALT, TC, TG, HDL-C, LDL-C, ApoB, FBG, FINS, HOMA-IR, and serum BMP-9 among the four groups (P<0.05). The level of serum BMP-9 was positively correlated with HDL-C, while the level of serum BMP-9 was negatively correlated with BMI, SBP, DBP, ALT, TC, TG, LDL-C, FBG, FINS, and HOMA-IR. Multiple stepwise regression analyses revealed that FINS, LDL-C, HDL-C, and BMI were independent factors impacting serum BMP-9 levels (P<0.05). Logistic regression analyses revealed that BMP-9 was a protective factor for T2DM paired with NAFLD, while HOMA-IR was a risk factor. CONCLUSION: Serum BMP-9 levels are significantly lower in the T2DM+NAFLD group when compared to other groups, and BMP-9 is an independent risk factor for T2DM paired with NAFLD.
format Online
Article
Text
id pubmed-9741848
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97418482022-12-12 Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Hao, Jianan Wang, Yichao Huo, Lijing Sun, Tiantian Zhen, Yunfeng Gao, Zhe Chen, Shuchun Ren, Luping Int J Gen Med Original Research OBJECTIVE: We aimed to examine the association between bone morphogenetic protein-9 (BMP-9) and type 2 diabetes mellitus (T2DM) in conjunction with non-alcoholic fatty liver disease (NAFLD) and insulin resistance (IR) and to identify evidence supporting the potential role of BMP-9 in the clinical prevention and treatment of T2DM in conjunction with NAFLD. METHODS: One hundred and twenty subjects were included in this study. We sorted all of the subjects into four groups of equal size (n=30 each). A trained expert assessed the height, weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP) of the subjects and computed the body mass index (BMI). All subjects had their fasting blood glucose (FBG), fasting insulin (FINS), serum BMP-9, and biochemical indices assessed. RESULTS: Significant variations were observed in BMI, SBP, DBP, ALT, TC, TG, HDL-C, LDL-C, ApoB, FBG, FINS, HOMA-IR, and serum BMP-9 among the four groups (P<0.05). The level of serum BMP-9 was positively correlated with HDL-C, while the level of serum BMP-9 was negatively correlated with BMI, SBP, DBP, ALT, TC, TG, LDL-C, FBG, FINS, and HOMA-IR. Multiple stepwise regression analyses revealed that FINS, LDL-C, HDL-C, and BMI were independent factors impacting serum BMP-9 levels (P<0.05). Logistic regression analyses revealed that BMP-9 was a protective factor for T2DM paired with NAFLD, while HOMA-IR was a risk factor. CONCLUSION: Serum BMP-9 levels are significantly lower in the T2DM+NAFLD group when compared to other groups, and BMP-9 is an independent risk factor for T2DM paired with NAFLD. Dove 2022-12-07 /pmc/articles/PMC9741848/ /pubmed/36514745 http://dx.doi.org/10.2147/IJGM.S385513 Text en © 2022 Hao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hao, Jianan
Wang, Yichao
Huo, Lijing
Sun, Tiantian
Zhen, Yunfeng
Gao, Zhe
Chen, Shuchun
Ren, Luping
Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
title Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
title_full Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
title_fullStr Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
title_full_unstemmed Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
title_short Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
title_sort circulating bone morphogenetic protein-9 is decreased in patients with type 2 diabetes and non-alcoholic fatty liver disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741848/
https://www.ncbi.nlm.nih.gov/pubmed/36514745
http://dx.doi.org/10.2147/IJGM.S385513
work_keys_str_mv AT haojianan circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease
AT wangyichao circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease
AT huolijing circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease
AT suntiantian circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease
AT zhenyunfeng circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease
AT gaozhe circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease
AT chenshuchun circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease
AT renluping circulatingbonemorphogeneticprotein9isdecreasedinpatientswithtype2diabetesandnonalcoholicfattyliverdisease